Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CET

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
12/13 MERCK : New Partnership to Fight Schistosomiasis in Ethiopia
12/12DJMERCK : Appoints Allan Gabor as Managing Director in China
12/12 MERCK : Allan Gabor Takes Over the Leadership of Merck KGaA, Darmstadt, Germany,..
12/11 REGENEUS LTD (ASX : RGS) Appoints Japan-Based Non-Executive Director with Extens..
12/11 MERCK : EMD Serono - John Walsh, M.D. Joins EMD Serono as Vice President of Neur..
12/11 MERCK : MilliporeSigma Signs Distribution Agreement with Avanti® Polar Lipids
12/10 REGENEUS LTD (ASX : RGS) Appoints Japan-Based Non-Executive Director with Extens..
12/07 MERCK : Darmstadt, Germany Receives Approval (Updated Registration) for Cladribi..
12/06 MERCK : EMD Serono Announces FDA 510(k) Clearance of Partner Genea Biomedx's Fer..
12/06 Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Up..
More news
News from SeekingAlpha
12/04 Merck KGaA's Mavenclad OK'd in Canada
12/01 Suitors preparing bids for Merck KgaA's consumer health unit
11/20 Roche Rocks On With More Good News
11/13 Orexigen Contrave up 10% on Contrave distribution deal with Merck KGaA for La..
11/13 Merck KGaA ADR 2017 Q3 - Results - Earnings Call Slides
Financials (€)
Sales 2017 15 341 M
EBIT 2017 3 265 M
Net income 2017 1 658 M
Debt 2017 9 825 M
Yield 2017 1,39%
P/E ratio 2017 20,62
P/E ratio 2018 20,69
EV / Sales 2017 1,41x
EV / Sales 2018 1,26x
Capitalization 11 782 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 108 €
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-10.38%13 672
ABBVIE53.23%153 782
KYOWA HAKKO KIRIN CO LTD31.21%10 815
JAZZ PHARMACEUTICALS PLC23.66%8 393
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD37.43%5 848
CONVATEC GROUP-10.13%5 566